Stanford and the FDA warn on compounded GLP-1 safety risks, from unapproved salt forms to 10 to 20x overdoses, as a 503B bulk-compounding ban advances in July 2026.
Stanford clinicians and the FDA warn that compounded GLP-1 drugs carry real safety risks: unapproved salt forms, untested additives, and self-drawn vials linked to accidental overdoses of 10 to 20 times the intended dose. The FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from bulk 503B compounding.
A July 2026 Stanford Medicine report and a parallel FDA rulemaking have sharpened the warning around compounded GLP-1 medications. Clinicians say compounded versions of semaglutide, tirzepatide, and liraglutide can differ chemically from the FDA-approved originals, and that patients drawing doses from multi-use vials at home have accidentally injected 10 to 20 times the intended amount.
The concern lands as the FDA advances a proposal, announced April 30, 2026, to permanently exclude these three drugs from the 503B Bulks List. That would block outsourcing facilities from mass-compounding them from bulk drug substances. For consumers, the practical question is not whether GLP-1 treatment works, but whether the specific product in the vial is the FDA-approved drug or an unapproved compounded copy.
On April 30, 2026, the FDA proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, the list of bulk substances that outsourcing facilities are allowed to compound. The agency said it found no clinical need for facilities to compound these drugs from bulk substances. The public comment window, originally set to close June 29, 2026, was extended to the end of July 2026.
Brand-name semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are FDA-approved. The compounded versions at issue are not FDA-approved: they were permitted only under temporary shortage authorizations during 2022 supply gaps. Semaglutide came off the shortage list in 2025 and tirzepatide in 2024, removing the legal basis for large-scale compounding of identical copies. The FDA has also sent warning letters to dozens of companies over false or misleading claims about compounded GLP-1 products.
Stanford clinicians flagged several safety gaps. Some compounders use salt forms such as semaglutide sodium, which the FDA says have not been proven safe and effective or approved for human use. Others add ingredients like vitamin B12, B6, niacinamide, glycine, or carnitine; a 2026 study found that tirzepatide and B12 can chemically bond into a new molecule not present in the approved drug. GLP-1s are fragile peptides prone to breaking down with heat, light, or improper handling, and compounded versions may degrade before reaching the patient.
Dosing is the sharpest risk. The FDA flagged cases where patients administered 10 to 20 times the prescribed dose simply by mis-measuring from a vial. In 2024, roughly 95 percent of GLP-1 adverse events were tied to how the product was dosed or administered rather than the drug itself. Endocrinologist Marina Basina, MD, said compounded GLP-1 use without medical supervision poses significant risk, and pharmacist Michael Blyumin, PharmD, noted that no legitimate manufacturer makes sublingual semaglutide.
The FDA has not issued a final rule. Watch for the agency's decision after the comment period closes at the end of July 2026, which will determine whether 503B outsourcing facilities are permanently barred from bulk-compounding these three GLP-1s. Smaller 503A pharmacies compounding for individual patients may continue under more restricted conditions, and liraglutide's status can shift if it remains on the shortage list. Anyone using or considering a GLP-1 should confirm with a licensed provider whether their product is the FDA-approved drug or a compounded version, and should never adjust a dose without medical supervision.